Total number of voting rights and share capital in H. Lundbeck A/S as of 29 February 2016
Valby, Denmark, 2016-02-29 13:21 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 29 February 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers’ Disclosure Obligations, H. Lundbeck A/S is required to publish the total number of voting rights and the size of the share capital in H. Lundbeck A/S as per the end of a month in which changes have occurred.
Referring to Corporate Release no. 579 dated 23 February 2016, please find below a statement regarding the total number of voting rights and share capital in H. Lundbeck A/S as per 29 February 2016.
| Number of shares (nominal value DKK 5) |
Nominal value (DKK) |
Number of votes | |
| Shares | 197,341,385 | 986,706,925 | 197,341,385 |
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Vice President, Investor Relations | Director, Corporate Communication |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 30 00 |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.
Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.
Vedhæftede filer:
Mest læste lige nu
Seneste nyheder
- 1 af 1176
- næste ›